Wayne Koberstein

  1. Companies To Watch: Ocelot Bio 1/3/2023

    Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.

  2. Biopharma Public Opinion, Pricing, Politics 12/1/2022

    Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.

  3. Pioneering In-House, Continuous Manufacturing 11/1/2022

    Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.

  4. Companies To Watch: iTolerance 11/1/2022

    iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.

  5. Companies To Watch: CytoAgents 10/3/2022

    CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.

  6. The Discovering CEO 10/3/2022

    In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.

  7. Nonprofit Pursues Oncology Drugs 9/1/2022

    RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

  8. Companies To Watch: Viking Therapeutics 9/1/2022

    Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.

  9. Companies To Watch: Priothera 8/1/2022

    Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.

  10. Living Diversity, Inside Mink Therapeutics 8/1/2022

    We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.